European Patent Office Discusses Patenting Artificial Intelligence 01/06/2018 by Monika Ermert for Intellectual Property Watch 1 Comment MUNICH — United States and Chinese patent practitioners this week called for considerations to change patent legislation and allow patenting algorithms in the future. They spoke at a 30 May conference of the European Patent Office in Munich on “Patenting Artificial Intelligence.”
EU Governments Reach Negotiating Stance On Copyright Reform 25/05/2018 by Dugie Standeford for Intellectual Property Watch 1 Comment European Union member states today reportedly agreed on their negotiating position on the proposed copyright directive, and early reactions are unenthusiastic.
Swiss Group Suggests Switzerland Use Compulsory Licences To Curb Cancer Drug Prices 24/05/2018 by Catherine Saez, Intellectual Property Watch Leave a Comment During a side event held alongside this week’s World Health Assembly, public health advocates proposed that Switzerland use compulsory licensing as a way to decrease what they said are exorbitant drug prices.
50 Years Of Global Health Progress – Interview With IFPMA Head Thomas Cueni 23/05/2018 by William New, Intellectual Property Watch Leave a Comment Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as “do-ers” and partners in global health progress. Cueni also talks about pricing and cost of R&D.
Five Years After The Indian Supreme Court’s Novartis Verdict 20/05/2018 by Patralekha Chatterjee for Intellectual Property Watch 13 Comments On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about patents and patients. India’s apex court delivered a 112-page landmark judgement which dismissed Swiss pharma giant Novartis AG’s appeal for a patent for its life-saving cancer drug marketed under brand name Glivec in most parts of the world. The Novartis case triggered a hugely polarising discourse around the world about a key feature of India’s patent regime.
TRIPS Flexibilities In High Demand 16/05/2018 by Intellectual Property Watch Leave a Comment Using flexibilities in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) has long been an issue of the developing world. But policymakers gathered at a meeting on access to health in Brussels today said there was an urgent need for European Union countries, too, to make more use of flexibilities.
Groups Target EU-Mercosur FTA To Advance Access To Health In Trade Deals 16/05/2018 by Monika Ermert for Intellectual Property Watch 12 Comments AIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of the planned free trade agreement between the Mercosur countries and the European Union. The EU-Mercosur negotiations might be the best chance as of now to advance an intellectual property agenda that is more favourable to access to health, says Pedro Villardi, coordinator on IP policy issues at the Associação Brasiliera Interdisciplinar de Aids Observatorio National de Politicas de Aids (ABIA).
EU-US Comparison & Guide On Copyright Link Liability – An Update 09/05/2018 by Intellectual Property Watch 1 Comment Ed Klaris and Alexia Bedat write: An update to our article reviewing US and European law/recent developments in link liability in both the copyright and defamation contexts and providing a checklist of questions an attorney (or editor) ought to ask before deciding, prepublication, whether a proposed link may lead to liability in the US and/or the EU. Updates include the recent Goldman v. Breitbart decision in which a Federal Judge concluded that embedding a Tweet can be copyright infringement.
Ukraine Eyes Patent Law Reform After Civil Society Push On Medicines Access 30/04/2018 by Dugie Standeford for Intellectual Property Watch 14 Comments Ukrainian lawmakers are poised to approve sweeping patent reform legislation, driven in large part by a push by patients’ groups for better access to affordable medicines and healthcare.
How To Discover Valuable Patents 27/04/2018 by Intellectual Property Watch Leave a Comment Bastian July writes: In May 1968, the submarine USS Scorpion disappeared after a tour of duty in the North Atlantic. The initial search area was a circle twenty miles wide and thousands of feet deep. Instead of asking one or two experts for input, Navy officer John Craven assembled a large group of independent experts with a wide range of knowledge. The group included mathematicians, submarine specialists, salvage men and many others. Combining their knowledge, Craven was able to estimate the submarine’s likely location. It was found 200 yards from the group’s collective estimate. But can you also turn to the Wisdom of the Crowd when it comes to discovering the fortunes lying hidden in patents?